Blair William & CO Beyond Spring Inc. Transaction History

Blair William & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$1.68 - $5.01 $44,814 - $133,641	-26,675 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.02 - $16.84 $788,040 - $3.3 Million	-196,030 Reduced 88.02%	26,675 $121,000
Q3 2021 Nov 12, 2021	SELL	$9.26 - $31.31 $1.92 Million - $6.51 Million	-207,875 Reduced 48.28%	222,705 $3.51 Million
Q2 2021 Aug 12, 2021	BUY	$9.37 - $12.12 $1.83 Million - $2.36 Million	194,930 Added 82.72%	430,580 $4.5 Million
Q1 2021 May 13, 2021	BUY	$10.61 - $15.77 $1.71 Million - $2.54 Million	161,150 Added 216.31%	235,650 $2.61 Million
Q4 2020 Feb 09, 2021	BUY	$10.21 - $17.31 $406,868 - $689,803	39,850 Added 115.01%	74,500 $909,000
Q3 2020 Nov 06, 2020	BUY	$9.99 - $16.13 $147,852 - $238,723	14,800 Added 74.56%	34,650 $461,000
Q2 2020 Aug 12, 2020	BUY	$11.21 - $18.15 $222,518 - $360,277	19,850 New	19,850 $299,000
Q1 2020 May 11, 2020	SELL	$9.68 - $18.47 $101,640 - $193,935	-10,500 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$11.83 - $18.68 $124,215 - $196,140	10,500 New	10,500 $163,000

5.77M

53.2K

2.5K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $91.5M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.